Text Size

Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults

This study is currently recruiting participants.
Verified October 2012 by National Institute of Allergy and Infectious Disease (NIAID)
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Disease (NIAID)
ClinicalTrials.gov Identifier:
NCT01574638
First received: April 6, 2012
Last updated: October 8, 2012
Last verified: October 2012
History of Changes
  Purpose

This study will evaluate two different ways to give rifapentine (RPT), a drug that may help shorten treatment duration for tuberculosis (TB) disease.


Condition Intervention Phase
Tuberculosis
 Drug: Rifapentine (RPT)
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Clinical Trial of the Pharmacokinetics of High-dose Daily Rifapentine, Given as a Single Dose or in Divided Doses to Healthy Volunteers

Resource links provided by NLM:

MedlinePlus related topics: Tuberculosis
Drug Information available for: Rifapentine
U.S. FDA Resources

Further study details as provided by National Institute of Allergy and Infectious Disease (NIAID):

Primary Outcome Measures:
  • RPT PK parameter: area under the curve over 24 hours (AUC 0 to 24h) [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 1, when given at a dose of 20 mg/kg once daily (Arm 1B) and when given at a dose of 10 mg/kg twice daily (Arm 1A)

  • RPT PK parameter: AUC 0 to 24h [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)

  • Grade 2 or higher signs and symptoms observed while on study beginning with the first dose of study drug and continuing through the follow-up period [ Time Frame: Measured through Day 84 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • RPT PK parameter: maximum observed plasma concentrations (Cmax) [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)

  • Cmin (trough) values [ Time Frame: Measured at Days 1, 7, 14, 43, 49, 56, 64, and 70 ] [ Designated as safety issue: No ]
  • Metabolizer status of human genetic variants/polymorphisms in gene SLCO1B1 and possibly other genes that are thought to affect PK of RIF [ Time Frame: Measured at Day 0 ] [ Designated as safety issue: No ]
  • RPT PK parameter: minimum observed plasma concentration (Cmin) [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)

  • RPT PK parameter: oral clearance (CL/F) [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)

  • RPT PK parameter: elimination half-life (T 1/2) [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)

  • RPT metabolite desacetyl-rifapentine (desRPT) PK parameter: AUC 0 to 24h [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)

  • RPT metabolite desRPT PK parameter: Cmax [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)

  • RPT metabolite desRPT PK parameter: Cmin [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)

  • RPT metabolite desRPT PK parameter: CL/F [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)

  • RPT metabolite desRPT PK parameter: T1/2 [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 1, when RPT is given at a dose of 20 mg/kg once daily (Arm 1B) and at a dose of 10 mg/kg twice daily (Arm 1A)

  • RPT PK parameter: Cmax [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)

  • RPT PK parameter: Cmin [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)

  • RPT PK parameter: CL/F [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)

  • RPT PK parameter: T1/2 [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)

  • RPT metabolite desRPT PK parameter: AUC 0 to 24h [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)

  • RPT metabolite desRPT PK parameter: Cmax [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)

  • RPT metabolite desRPT PK parameter: Cmin [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)

  • RPT metabolite desRPT PK parameter: CL/F [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)

  • RPT metabolite desRPT PK parameter: T1/2 [ Time Frame: Measured at Days 14 and 56 ] [ Designated as safety issue: No ]
    Measured in Group 2, when RPT is given at a dose of 15 mg/kg once daily with a boiled egg (Arm 2A) and at a dose of 15 mg/kg once daily with a low-fat meal (Arm 2B)

  • RPT and its metabolite desRPT PK parameter AUC 0 to 24h at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 ) [ Time Frame: Measured at Days 1, 14, 43, 56, and 70 ] [ Designated as safety issue: No ]
  • RPT and its metabolite desRPT PK parameter Cmax at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 ) [ Time Frame: Measured at Days 1, 14, 43, 56, and 70 ] [ Designated as safety issue: No ]
  • RPT and its metabolite desRPT PK parameter Cmin at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 ) [ Time Frame: Measured at Days 1, 14, 43, 56, and 70 ] [ Designated as safety issue: No ]
  • RPT and its metabolite desRPT PK parameter CL/F at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 ) [ Time Frame: Measured at Days 1, 14, 43, 56, and 70 ] [ Designated as safety issue: No ]
  • RPT and its metabolite desRPT PK parameter T1/2 at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 ) [ Time Frame: Measured at Days 1, 14, 43, 56, and 70 ] [ Designated as safety issue: No ]
  • RPT and its metabolite desRPT PK parameter area under the curve extrapolated to infinity (AUC 0 to inf) [ Time Frame: Measured after single dose on Days 1 and 43 ] [ Designated as safety issue: No ]
  • RPT and its metabolite desRPT PK parameter CL/F [ Time Frame: Measured after single dose on Days 1 and 43 ] [ Designated as safety issue: No ]
  • RPT and its metabolite desRPT PK parameter T1/2 [ Time Frame: Measured after single dose on Days 1 and 43 ] [ Designated as safety issue: No ]
  • RPT and its metabolite desRPT PK parameter AUC 0 to 24h [ Time Frame: Measured after multiple dose on Days 14 and 56 ] [ Designated as safety issue: No ]
  • RPT and its metabolite desRPT PK parameter CL/F [ Time Frame: Measured after multiple dose on Days 14 and 56 ] [ Designated as safety issue: No ]
  • RPT and its metabolite desRPT PK parameter T1/2 [ Time Frame: Measured after multiple dose on Days 14 and 56 ] [ Designated as safety issue: No ]

Estimated Enrollment: 48
Arms Assigned Interventions
Experimental: Arm 1B
Participants in Arm 1B will receive RPT based on weight at entry, at a dose of 20 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 10 mg/kg twice daily with low-fat meals.
 Drug: Rifapentine (RPT)
Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.
Experimental: Arm 1A
Participants in Arm 1A will receive RPT based on weight at entry, at a dose of 10 mg/kg twice daily with low-fat meals, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 20 mg/kg once daily with a low-fat breakfast.
 Drug: Rifapentine (RPT)
Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.
Experimental: Arm 2A
Participants in Arm 2A will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a boiled egg, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 70, at a dose of 15 mg/kg once daily with a low-fat breakfast.
 Drug: Rifapentine (RPT)
Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.
Experimental: Arm 2B
Participants in Arm 2B will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 15 mg/kg once daily with a boiled egg.
 Drug: Rifapentine (RPT)
Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.

Detailed Description:

TB continues to be a major global health problem, with an estimated 9.4 million new cases and 1.3 million deaths from TB in 2009. Effective treatment is available, but the current standard therapy consists of 4 different drugs that must be given for 6 months to be effective. RPT is a rifamycin antibiotic approved by the Food and Drug Administration (FDA) to be given twice weekly during the intensive phase of TB treatment and once weekly during the continuation phase of TB treatment. However, studies using this regimen have seen high relapse rates of TB; use of higher and/or more frequent doses may be necessary to attain higher cure rates. This study will evaluate 2 strategies for optimizing RPT exposure: dividing the daily dose in order to increase absorption/overall drug exposure and providing the dose together with food.

Participants will be randomly assigned to one of 4 arms: Arm 1A, Arm 1B, Arm 2A, or Arm 2B. The first 12 participants who indicate that they are willing to remain on the study for up to 12 weeks will be assigned to Arm 2A; all others will be randomized to Arm 1A, 1B, or 2B. Participants in all arms will receive daily RPT from Day 1 to 14, followed by a washout period from Day 15 to 42 during which no RPT will be given, followed by a second period of daily RPT from Day 43 to 56 (and continuing through Day 70 for participants in Arm 2A). Arms 1A and 2B will evaluate twice-daily versus once-daily RPT taken with low-fat meals; Arms 2A and 2B will evaluate once-daily RPT given with an egg versus with a low-fat breakfast.

Total study duration will range from 63 to 70 days for Arms 1A, 1B, and 2B, with 10 study visits: 4 intensive pharmacokinetic (PK) sampling visits (at Days 0 to 2, 13 to 15, 42 to 44, and 55 to 57) and 6 other visits at screening and Days 7, 21, 35, and 49, with the final visit between Days 63 and 70. Total study duration for Arm 2A will range from 77 to 84 days, with 12 study visits: 5 intensive PK sampling visits (over Days 0 to 2, 13 to 15, 42 to 44, 55 to 57, and 69 to 71) and 7 other visits at screening and Days 7, 21, 35, 49, and 64, with the final visit between Days 77 and 84. Intensive PK visits will require the participant to be admitted to the clinic for 1 or 2 nights and to have blood collected multiple times. Interim study visits may consist of giving a medical history, undergoing a physical exam and blood collection, and undergoing a pregnancy test for women of reproductive potential. Participants also will be required to keep a diary of the times they took outpatient study drugs, any medications taken other than the study drug, and any symptoms experienced.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Weight of 50 to 100 kg, inclusive
  • Absence of HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit within 21 days prior to study entry. NOTE: The term "licensed" refers to a U.S. FDA-approved kit.

  • Females of reproductive potential (defined as women who have not been postmenopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months, and do not have documentation of having undergone a sterilization procedure [e.g., hysterectomy or bilateral oophorectomy or salpingectomy]) must have a negative serum or urine beta-human choriogonadotropin (β-HCG) pregnancy test performed within 48 hours prior to entry. The urine test must have a sensitivity of at least 25 mlU/mL and be performed at a laboratory with Clinical Laboratory Improvement Amendment (CLIA) certification or its equivalent.

    • If participating in sexual activity that could lead to pregnancy, females must agree to use at least one reliable form of contraceptive while receiving the protocol-specified medications and for 1 week after stopping study medications. At least one (but preferably two) of the following contraceptives MUST be used appropriately:
    • Condoms (male or female) with or without a spermicidal agent
    • Diaphragm or cervical cap with spermicide

    • Intrauterine device (IUD)

      • NOTE: Hormone-based contraceptives are contraindicated with RPT and therefore may not be used as a form of contraception during this study.
  • Ability and willingness of volunteer to provide written informed consent

  • Laboratory values obtained within 21 days prior to entry:

    • Serum alanine aminotransferase (ALT) less than or equal to 1.2 times the upper limit of normal (ULN)
    • Total bilirubin level less than or equal to 1.2 times the ULN
    • Serum creatinine less than or equal to 1.5 mg/dL
    • Hemoglobin greater than or equal to 12.0 g/dL for men, greater than or equal to 11.0 g/dL for women
    • Platelet count greater than or equal to 125,000/mm^3
    • Absolute neutrophil count greater than or equal to 1,250/mm^3
    • Serum albumin greater than or equal to 3.5 g/dL
    • Hepatitis C antibody negative

Exclusion Criteria:

  • Breastfeeding
  • Within 30 days prior to entry, use of any prescription medication known to inhibit or induce cytochrome P (CYP)3A metabolizing enzymes (refer to the manufacturers' package inserts for individual drugs). See list posted on the A5311 protocol-specific webpage (PSWP).
  • Known intolerance of or allergy to chicken eggs
  • Use of rifamycin antibiotics within 60 days prior to entry
  • Planned use during the study of prescription medications, herbal supplements, nutritional supplements, or over-the-counter medications except for multivitamins, acetaminophen (up to 650 mg every 6 hours as an analgesic), ibuprofen (up to 600 mg twice daily), naproxen (up to 500 mg twice daily for pain or headache), or Benadryl (diphenhydramine, up to 25 mg daily for insomnia or seasonal allergies)
  • Within 14 days prior to study entry, hospitalization for any reason or pharmacotherapy for serious illness
  • Within 14 days prior to study entry, use of any prescription medication(s)
  • Receipt of any investigational study drug within 21 days prior to study entry
  • Known allergy/sensitivity or any hypersensitivity to rifamycins, including rifampin, rifabutin, and rifapentine
  • Presence of any condition interfering with normal gastrointestinal anatomy or motility that could interfere with drug absorption or excretion (including cholecystectomy, peptic ulceration, inflammatory bowel disease, or pancreatitis)
  • History or evidence of clinically significant (as determined by site investigator) cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, or immunologic disease(s)
  • Any medical condition that, in the opinion of the site investigator, would interfere with the participant's ability to participate in the study
  • Active illicit drug use or dependence or alcohol dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
  • History of TB infection or site investigator suspicion of current active TB
  • Inability to abstain from grapefruit and grapefruit juice for the duration of the study
  • Inability to adhere to the dietary requirements of the study (e.g., low-fat meal or boiled egg prior to drug doses during the study drug administration periods)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01574638

Locations
United States, California
Ucsd, Avrc Crs Recruiting
San Diego, California, United States, 92103
Contact: Jill Kunkel     619-543-3094     jkunkel@ucsd.edu    
United States, Maryland
Johns Hopkins Adult AIDS CRS Recruiting
Baltimore, Maryland, United States, 21287
Contact: Ilene Wiggins, RN     410-614-2766     imp@jhmi.edu    
United States, North Carolina
Unc Aids Crs Recruiting
Chapel Hill, North Carolina, United States, 27514
Contact: Cheryl J Marcus, BSN, RN     919-843-8761     cjm@med.unc.edu    
United States, Tennessee
Vanderbilt Therapeutics CRS Recruiting
Nashville, Tennessee, United States, 37204
Contact: Deborah Sutherland, RN, BSN, CCRP         deborah.sutherland@vanderbilt.edu    
Sponsors and Collaborators
National Institute of Allergy and Infectious Disease (NIAID)
  More Information

Publications:

Responsible Party: National Institute of Allergy and Infectious Disease (NIAID)
ClinicalTrials.gov Identifier: NCT01574638     History of Changes
Other Study ID Numbers: A5311, 11859, ACTG5311
Study First Received: April 6, 2012
Last Updated: October 8, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Rifapentine
Antibiotics, Antitubercular
 Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antitubercular Agents
Leprostatic Agents

ClinicalTrials.gov processed this record on October 17, 2012